Biomarkers of Microbiome Disruption for Patient Stratification in Clinical Trials of Microbiome Therapeutics in IBD

Time: 4:30 pm
day: Conference Day One


  • Microbiome heterogeneity in structural, functional, and immuno-modulatory properties in IBD
  • Baseline biomarkers predictive of microbiome therapeutic pharmacodynamics in IBD
  • Relating microbiome disruption and immuno-modulatory properties to inform patient stratification